147 related articles for article (PubMed ID: 32147798)
1. CRISPR/Cas9-Based Gene Engineering of Human Natural Killer Cells: Protocols for Knockout and Readouts to Evaluate Their Efficacy.
Lambert M; Leijonhufvud C; Segerberg F; Melenhorst JJ; Carlsten M
Methods Mol Biol; 2020; 2121():213-239. PubMed ID: 32147798
[TBL] [Abstract][Full Text] [Related]
2. Ex Vivo Expansion and CRISPR-Cas9 Genome Editing of Primary Human Natural Killer Cells.
Huang RS; Lai MC; Lin S
Curr Protoc; 2021 Sep; 1(9):e246. PubMed ID: 34529358
[TBL] [Abstract][Full Text] [Related]
3. High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells.
Clara JA; Levy ER; Reger R; Barisic S; Chen L; Cherkasova E; Chakraborty M; Allan DSJ; Childs R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35135865
[TBL] [Abstract][Full Text] [Related]
4. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges.
Zhi L; Su X; Yin M; Zhang Z; Lu H; Niu Z; Guo C; Zhu W; Zhang X
Cell Immunol; 2021 Nov; 369():104436. PubMed ID: 34500148
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9-Mediated TIM3 Knockout in Human Natural Killer Cells Enhances Growth Inhibitory Effects on Human Glioma Cells.
Morimoto T; Nakazawa T; Matsuda R; Nishimura F; Nakamura M; Yamada S; Nakagawa I; Park YS; Tsujimura T; Nakase H
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800561
[TBL] [Abstract][Full Text] [Related]
6. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
7. Engineering NK-92 Cell by Upregulating CXCR2 and IL-2 Via CRISPR-Cas9 Improves Its Antitumor Effects as Cellular Immunotherapy for Human Colon Cancer.
Gao L; Yang L; Zhang S; Ge Z; Su M; Shi Y; Wang X; Huang C
J Interferon Cytokine Res; 2021 Dec; 41(12):450-460. PubMed ID: 34935484
[TBL] [Abstract][Full Text] [Related]
8. CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells.
Mohammadian Gol T; Kim M; Sinn R; Ureña-Bailén G; Stegmeyer S; Gratz PG; Zahedipour F; Roig-Merino A; Antony JS; Mezger M
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003255
[TBL] [Abstract][Full Text] [Related]
9. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins.
Naeimi Kararoudi M; Dolatshad H; Trikha P; Hussain SA; Elmas E; Foltz JA; Moseman JE; Thakkar A; Nakkula RJ; Lamb M; Chakravarti N; McLaughlin KJ; Lee DA
J Vis Exp; 2018 Jun; (136):. PubMed ID: 29985369
[TBL] [Abstract][Full Text] [Related]
10. Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications.
Kumar A; Lee SJ; Liu Q; Chan AKN; Pokharel SP; Yu J; Chen CW; Swaminathan S
STAR Protoc; 2021 Dec; 2(4):100874. PubMed ID: 34746857
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9-mediated genome editing in sea urchins.
Lin CY; Oulhen N; Wessel G; Su YH
Methods Cell Biol; 2019; 151():305-321. PubMed ID: 30948015
[TBL] [Abstract][Full Text] [Related]
12. Application of CRISPR/Cas9 Genome Editing to Improve Recombinant Protein Production in CHO Cells.
Grav LM; la Cour Karottki KJ; Lee JS; Kildegaard HF
Methods Mol Biol; 2017; 1603():101-118. PubMed ID: 28493126
[TBL] [Abstract][Full Text] [Related]
13. One-step generation of triple knockout CHO cell lines using CRISPR/Cas9 and fluorescent enrichment.
Grav LM; Lee JS; Gerling S; Kallehauge TB; Hansen AH; Kol S; Lee GM; Pedersen LE; Kildegaard HF
Biotechnol J; 2015 Sep; 10(9):1446-56. PubMed ID: 25864574
[TBL] [Abstract][Full Text] [Related]
14. Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research.
Eun K; Park MG; Jeong YW; Jeong YI; Hyun SH; Hwang WS; Kim SH; Kim H
BMC Biotechnol; 2019 Jan; 19(1):1. PubMed ID: 30606176
[TBL] [Abstract][Full Text] [Related]
15. Assessment of two CRISPR-Cas9 genome editing protocols for rapid generation of Trypanosoma cruzi gene knockout mutants.
Burle-Caldas GA; Soares-Simões M; Lemos-Pechnicki L; DaRocha WD; Teixeira SMR
Int J Parasitol; 2018 Jul; 48(8):591-596. PubMed ID: 29577891
[TBL] [Abstract][Full Text] [Related]
16. Drug target validation in primary human natural killer cells using CRISPR RNP.
Rautela J; Surgenor E; Huntington ND
J Leukoc Biol; 2020 Oct; 108(4):1397-1408. PubMed ID: 33463756
[TBL] [Abstract][Full Text] [Related]
17. CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.
Bexte T; Alzubi J; Reindl LM; Wendel P; Schubert R; Salzmann-Manrique E; von Metzler I; Cathomen T; Ullrich E
Oncoimmunology; 2022; 11(1):2081415. PubMed ID: 35694192
[TBL] [Abstract][Full Text] [Related]
18. Generation of Functional Gene Knockout Melanoma Cell Lines by CRISPR-Cas9 Gene Editing.
Hargadon KM; Bushhouse DZ; Johnson CE; Williams CJ
Methods Mol Biol; 2021; 2265():25-46. PubMed ID: 33704703
[TBL] [Abstract][Full Text] [Related]
19. CIS deletion by CRISPR/Cas9 enhances human primary natural killer cell functions against allogeneic glioblastoma.
Nakazawa T; Morimoto T; Maeoka R; Matsuda R; Nakamura M; Nishimura F; Ouji N; Yamada S; Nakagawa I; Park YS; Ito T; Nakase H; Tsujimura T
J Exp Clin Cancer Res; 2023 Aug; 42(1):205. PubMed ID: 37563692
[TBL] [Abstract][Full Text] [Related]
20. Efficient and stable CRISPR/Cas9-mediated genome-editing of human type 2 innate lymphoid cells.
Audouze-Chaud J; Mathews JA; Crome SQ
Front Immunol; 2023; 14():1275413. PubMed ID: 37868976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
